Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma

There was no difference in PFS or OS between the UPSCBR + and UPSCBR − cohorts. We did not demonstrate significant OS or PFS differences in women who took tamoxifen prior to their endometrial cancer diagnosis. These findings have implications for counseling, and should be encouraging to women who are facing their second cancer diagnosis.